HUE039677T2 - Humanizált anti-CD28-ellenanyagok - Google Patents
Humanizált anti-CD28-ellenanyagokInfo
- Publication number
- HUE039677T2 HUE039677T2 HUE11707918A HUE11707918A HUE039677T2 HU E039677 T2 HUE039677 T2 HU E039677T2 HU E11707918 A HUE11707918 A HU E11707918A HU E11707918 A HUE11707918 A HU E11707918A HU E039677 T2 HUE039677 T2 HU E039677T2
- Authority
- HU
- Hungary
- Prior art keywords
- humanized antibodies
- humanized
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10290080A EP2361935A1 (en) | 2010-02-18 | 2010-02-18 | Anti-CD28 humanized antibodies |
EP10290389 | 2010-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE039677T2 true HUE039677T2 (hu) | 2019-01-28 |
Family
ID=44482493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11707918A HUE039677T2 (hu) | 2010-02-18 | 2011-02-16 | Humanizált anti-CD28-ellenanyagok |
Country Status (16)
Country | Link |
---|---|
US (3) | US8785604B2 (hu) |
EP (2) | EP3428192B1 (hu) |
JP (1) | JP5992340B2 (hu) |
CA (1) | CA2788544C (hu) |
CY (1) | CY1120707T1 (hu) |
DK (1) | DK2536764T3 (hu) |
ES (2) | ES2896149T3 (hu) |
HR (1) | HRP20181360T1 (hu) |
HU (1) | HUE039677T2 (hu) |
LT (1) | LT2536764T (hu) |
PL (1) | PL2536764T3 (hu) |
PT (1) | PT2536764T (hu) |
RS (1) | RS57667B1 (hu) |
SI (1) | SI2536764T1 (hu) |
TR (1) | TR201811185T4 (hu) |
WO (1) | WO2011101791A1 (hu) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2210902A1 (en) * | 2009-01-14 | 2010-07-28 | TcL Pharma | Recombinant monovalent antibodies |
LT2536764T (lt) | 2010-02-18 | 2018-10-25 | Ose Immunotherapeutics | Anti-cd28 humanizuoti antikūnai |
WO2014120916A1 (en) * | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Pegylated domain antibodies monovalent for cd28 binding and methods of use |
US9963497B2 (en) * | 2013-12-06 | 2018-05-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28 |
WO2017103003A1 (en) * | 2015-12-15 | 2017-06-22 | Ose Immunotherapeutics | Anti-cd28 humanized antibodies formulated for administration to humans |
EP3481862A4 (en) | 2016-07-06 | 2020-08-12 | Celgene Corporation | LOW IMMUNOGENIC ANTIBODIES AND USES THEREOF |
CN115305229A (zh) | 2016-07-13 | 2022-11-08 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
CA3044526A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
US20210261645A1 (en) * | 2018-05-23 | 2021-08-26 | Manysmart Therapeutics, Inc. | Bispecific t cell engager and uses thereof |
WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
WO2022006179A1 (en) | 2020-06-29 | 2022-01-06 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
WO2022040482A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
WO2023278641A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
AU2022324456A1 (en) | 2021-08-05 | 2024-02-15 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
JP2024534910A (ja) | 2021-09-03 | 2024-09-26 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコlamp1抗体およびその使用 |
EP4395810A1 (en) | 2021-09-03 | 2024-07-10 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
CA3234825A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods of generating cells |
WO2023114701A2 (en) * | 2021-12-13 | 2023-06-22 | BioLegend, Inc. | Cd28 binding antibodies and antigen binding fragments thereof |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
US20240228620A1 (en) | 2022-10-06 | 2024-07-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6776990B2 (en) * | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
CZ20031909A3 (cs) * | 2000-12-14 | 2003-11-12 | Fujisawa Pharmaceutical Co., Ltd. | Tlumené protilátky proti CD 28 a jejich použití |
EP1345969B1 (fr) * | 2000-12-26 | 2010-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticorps anti-cd28 |
US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
TW200732350A (en) * | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
LT2700651T (lt) * | 2008-07-18 | 2019-06-25 | Bristol-Myers Squibb Company | Vienvalentinės cd28 prisijungimo atžvilgiu kompozicijos ir panaudojimo būdai |
JP2012512640A (ja) * | 2008-12-19 | 2012-06-07 | ノバルティス アーゲー | 自己免疫および炎症性障害の処置に使用するための可溶性ポリペプチド |
EP2210902A1 (en) * | 2009-01-14 | 2010-07-28 | TcL Pharma | Recombinant monovalent antibodies |
LT2536764T (lt) * | 2010-02-18 | 2018-10-25 | Ose Immunotherapeutics | Anti-cd28 humanizuoti antikūnai |
WO2017103003A1 (en) * | 2015-12-15 | 2017-06-22 | Ose Immunotherapeutics | Anti-cd28 humanized antibodies formulated for administration to humans |
-
2011
- 2011-02-16 LT LTEP11707918.6T patent/LT2536764T/lt unknown
- 2011-02-16 HU HUE11707918A patent/HUE039677T2/hu unknown
- 2011-02-16 ES ES18177022T patent/ES2896149T3/es active Active
- 2011-02-16 ES ES11707918.6T patent/ES2680570T3/es active Active
- 2011-02-16 CA CA2788544A patent/CA2788544C/en active Active
- 2011-02-16 RS RS20180994A patent/RS57667B1/sr unknown
- 2011-02-16 EP EP18177022.3A patent/EP3428192B1/en active Active
- 2011-02-16 EP EP11707918.6A patent/EP2536764B1/en active Active
- 2011-02-16 TR TR2018/11185T patent/TR201811185T4/tr unknown
- 2011-02-16 WO PCT/IB2011/050646 patent/WO2011101791A1/en active Application Filing
- 2011-02-16 JP JP2012553431A patent/JP5992340B2/ja active Active
- 2011-02-16 PL PL11707918T patent/PL2536764T3/pl unknown
- 2011-02-16 PT PT117079186T patent/PT2536764T/pt unknown
- 2011-02-16 DK DK11707918.6T patent/DK2536764T3/en active
- 2011-02-16 US US13/577,103 patent/US8785604B2/en active Active
- 2011-02-16 SI SI201131521T patent/SI2536764T1/sl unknown
-
2014
- 2014-07-08 US US14/326,119 patent/US9562098B2/en active Active
-
2016
- 2016-12-21 US US15/386,998 patent/US10364287B2/en active Active
-
2018
- 2018-08-24 HR HRP20181360TT patent/HRP20181360T1/hr unknown
- 2018-09-28 CY CY181101006T patent/CY1120707T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2896149T3 (es) | 2022-02-24 |
EP3428192A1 (en) | 2019-01-16 |
LT2536764T (lt) | 2018-10-25 |
EP2536764B1 (en) | 2018-07-04 |
HRP20181360T1 (hr) | 2018-11-02 |
US20130078236A1 (en) | 2013-03-28 |
SI2536764T1 (sl) | 2018-11-30 |
JP5992340B2 (ja) | 2016-09-14 |
TR201811185T4 (tr) | 2018-08-27 |
RS57667B1 (sr) | 2018-11-30 |
US20150071916A1 (en) | 2015-03-12 |
US8785604B2 (en) | 2014-07-22 |
DK2536764T3 (en) | 2018-09-17 |
EP3428192B1 (en) | 2021-08-11 |
WO2011101791A1 (en) | 2011-08-25 |
EP2536764A1 (en) | 2012-12-26 |
CA2788544A1 (en) | 2011-08-25 |
JP2013519389A (ja) | 2013-05-30 |
CA2788544C (en) | 2019-03-05 |
PT2536764T (pt) | 2018-08-10 |
PL2536764T3 (pl) | 2018-12-31 |
CY1120707T1 (el) | 2019-12-11 |
US9562098B2 (en) | 2017-02-07 |
US20170114136A1 (en) | 2017-04-27 |
US10364287B2 (en) | 2019-07-30 |
ES2680570T3 (es) | 2018-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181360T1 (hr) | Anti-cd28 humanizirana protutijela | |
IL220404A (en) | Antiseptic antibodies | |
HK1182625A1 (en) | Bispecific antibodies | |
AP4082A (en) | Anti-cd40 antibodies | |
IL222222A0 (en) | Antibodies against csf-1r | |
ZA201209004B (en) | Anti-fgfr2 antibodies | |
GB201000467D0 (en) | Antibodies | |
IL221371A0 (en) | Anti-lrp6 antibodies | |
IL217919A0 (en) | Humanized anti-cdcp1 antibodies | |
GB201020738D0 (en) | Antibodies | |
HK1194388A1 (zh) | 抗缺刻蛋白 抗體 | |
PL2603528T3 (pl) | Przeciwciała Fab-glikozylowane | |
GB201002238D0 (en) | Antibodies | |
ZA201302459B (en) | Antibodies | |
HK1185088A1 (zh) | 人源化 抗體 | |
HK1175486A1 (zh) | 抗腫瘤壞死因子α的人源化抗體 | |
GB201020751D0 (en) | Antibodies | |
GB201005062D0 (en) | Antibodies |